Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FinlandBack to Finland

Clinical trials in Seinajoki – page 2

33 clinical trials in Seinajoki, Finland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Seinajoki at a glance
33
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

33 trials in Seinajoki

Open in trial search

Appendicitis

Not yet recruiting

Study on Antibiotic Treatment for Uncomplicated Acute Appendicitis Using Levofloxacin, Ertapenem, and Moxifloxacin in Adult Patients

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years
  • Substances:Ertapenem
  • Sponsor:Turku University Hospital

Appendicitis

Not yet recruiting

Study on Moxifloxacin for Treating Uncomplicated Acute Appendicitis in Adults

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years
  • Substances:Moxifloxacin
  • Sponsor:Turku University Hospital

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine for Respiratory Syncytial Virus in Adults Aged 60 and Older

Not recruiting
Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:GlaxoSmithKline Biologicals

Respiratory syncytial virus infection+3

Not recruiting

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:GlaxoSmithKline Biologicals

Cytomegalovirus immunisation

Not recruiting

Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

Registered drug
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Sodium Chloride
  • Sponsor:Moderna Inc.

Type 2 diabetes mellitus

Not recruiting

A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Meningococcal infection

Not recruiting

Study of rMenB+OMV NZ meningococcal group B vaccine immune response and safety in previously vaccinated healthy participants aged 10 to 20 years

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Outer Membrane Vesicles (Omv) From Neisseria Meningitidis Group B Strain Nz98/254 Measured As Amount Of Total Protein Containing The Pora P1.4 Adsorbed On Aluminium Hydroxide
  • Sponsor:GlaxoSmithKline Biologicals

Influenza immunisation

Not recruiting

Study on the Safety and Immune Response of a High-Dose Influenza Vaccine in Adults Aged 60 and Over, Comparing Trivalent Influenza Vaccine with a Drug Combination

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:A/Victoria/4897/2022 (H1N1)Pdm09-Like Strain (A/Victoria/4897/2022, Ivr-238)
  • Sponsor:Abbott Biologicals B.V.

Respiratory syncytial virus infection

Not recruiting

Study on the Effectiveness and Safety of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Toddlers

Investigational
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:534
  • Sponsor:Sanofi Pasteur Inc.

Meningococcal immunisation

Not recruiting

Safety and immunogenicity study of Pentavalent Meningococcal ABCYW vaccine (MenPenta SD and MenPenta fHD) compared to licensed meningococcal vaccines in infants, toddlers and children

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:Diphtheria toxoid
  • Sponsor:Sanofi Pasteur Inc.

Pneumococcal immunisation

Not recruiting

Study on the Safety and Immune Response of a 21-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:Pneumococcal oligosaccharide serotype 18C conjugated to CRM197
  • Sponsor:Sanofi Pasteur Inc.

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Seinajoki

What the registry says about research in the country

01 Infectious Disease Prevention

Extensive research focusing on vaccine development against multiple infectious diseases, including studies on RSV, influenza, and pneumococcal infections. Clinical trials are evaluating novel vaccination strategies for different age groups.

  • Respiratory Syncytial Virus Vaccines
  • Influenza Prevention
  • Meningococcal Protection

Multiple studies are assessing immunogenicity and safety profiles in various populations from infants to older adults.

02 Oncology Research

Innovative investigations into prostate cancer treatments, including studies on hormone therapy resistance and radiation-based interventions. Research focuses on both metastatic and non-metastatic disease states.

  • Advanced Prostate Cancer Therapies
  • Hormone Treatment Studies
  • Radiation-based Interventions

Trials are exploring combination therapies and novel treatment approaches for various stages of cancer progression.

03 Emergency Medicine

Studies examining acute medical conditions, including appendicitis management and myocardial infarction interventions. Research is focused on optimizing treatment protocols and improving patient outcomes.

  • Acute Abdomen Diagnostics
  • Cardiac Emergency Care
  • Antibiotic Treatment Protocols

Investigations are comparing traditional and innovative approaches to emergency medical conditions.

Back to FinlandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.